Overview

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

Status:
Completed

Trial end date:
2017-10-30

Target enrollment:

Participant gender:

Summary

The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin) in a cohort of early-treated HIV positive individuals.

Phase:

Phase 1

Details

Lead Sponsor:

IrsiCaixa

Collaborators:

BCN Checkpoint
BCN-Checkpoint
Fundacio Lluita Contra la SIDA
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Germans Trias i Pujol Hospital
HIVACAT
Hospital Clinic of Barcelona
Hospital de Sant Pau
University of Oxford

Treatments:

Histone Deacetylase Inhibitors
Romidepsin
Vaccines